Literature DB >> 30684464

Troponin I modulation of cardiac performance: Plasticity in the survival switch.

Brandon J Biesiadecki1, Margaret V Westfall2.   

Abstract

Signaling complexes targeting the myofilament are essential in modulating cardiac performance. A central target of this signaling is cardiac troponin I (cTnI) phosphorylation. This review focuses on cTnI phosphorylation as a model for myofilament signaling, discussing key gaps and future directions towards understanding complex myofilament modulation of cardiac performance. Human heart cTnI is phosphorylated at 14 sites, giving rise to a complex modulatory network of varied functional responses. For example, while classical Ser23/24 phosphorylation mediates accelerated relaxation, protein kinase C phosphorylation of cTnI serves as a brake on contractile function. Additionally, the functional response of cTnI multi-site phosphorylation cannot necessarily be predicted from the response of individual sites alone. These complexities underscore the need for systematically evaluating single and multi-site phosphorylation on myofilament cellular and in vivo contractile function. Ultimately, a complete understanding of these multi-site responses requires work to establish site occupancy and dominance, kinase/phosphatase signaling balance, and the function of adaptive secondary phosphorylation. As cTnI phosphorylation is essential for modulating cardiac performance, future insight into the complex role of cTnI phosphorylation is important to establish sarcomere signaling in the healthy heart as well as identification of novel myofilament targets in the treatment of disease.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac; Contraction; Phosphorylation; Relaxation; Signaling; Troponin I

Mesh:

Substances:

Year:  2019        PMID: 30684464      PMCID: PMC6403007          DOI: 10.1016/j.abb.2019.01.025

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  70 in total

1.  Effects of PKA phosphorylation of cardiac troponin I and strong crossbridge on conformational transitions of the N-domain of cardiac troponin C in regulated thin filaments.

Authors:  Wen-Ji Dong; Jayant James Jayasundar; Jianli An; Jun Xing; Herbert C Cheung
Journal:  Biochemistry       Date:  2007-08-03       Impact factor: 3.162

Review 2.  Calcium, thin filaments, and the integrative biology of cardiac contractility.

Authors:  Tomoyoshi Kobayashi; R John Solaro
Journal:  Annu Rev Physiol       Date:  2005       Impact factor: 19.318

3.  Troponin I phosphorylation in the normal and failing adult human heart.

Authors:  G S Bodor; A E Oakeley; P D Allen; D L Crimmins; J H Ladenson; P A Anderson
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

4.  Phosphorylation of troponin I and the inotropic effect of adrenaline in the perfused rabbit heart.

Authors:  R J Solaro; A J Moir; S V Perry
Journal:  Nature       Date:  1976-08-12       Impact factor: 49.962

5.  alpha-Adrenergic response and myofilament activity in mouse hearts lacking PKC phosphorylation sites on cardiac TnI.

Authors:  David E Montgomery; Beata M Wolska; W Glen Pyle; Brian B Roman; Jasmine C Dowell; Peter M Buttrick; Alan P Koretsky; Pedro Del Nido; R John Solaro
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-06       Impact factor: 4.733

6.  Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation.

Authors:  R Zhang; J Zhao; A Mandveno; J D Potter
Journal:  Circ Res       Date:  1995-06       Impact factor: 17.367

7.  Cardiac troponin I, isolated from bovine heart, contains two adjacent phosphoserines. A first example of phosphoserine determination by derivatization to S-ethylcysteine.

Authors:  K Swiderek; K Jaquet; H E Meyer; L M Heilmeyer
Journal:  Eur J Biochem       Date:  1988-09-15

8.  Left ventricular and myocardial function in mice expressing constitutively pseudophosphorylated cardiac troponin I.

Authors:  Jonathan A Kirk; Guy A MacGowan; Caroline Evans; Stephen H Smith; Chad M Warren; Ranganath Mamidi; Murali Chandra; Alexandre F R Stewart; R John Solaro; Sanjeev G Shroff
Journal:  Circ Res       Date:  2009-10-22       Impact factor: 17.367

9.  Protein kinase C phosphorylation of cardiac troponin I or troponin T inhibits Ca2(+)-stimulated actomyosin MgATPase activity.

Authors:  T A Noland; J F Kuo
Journal:  J Biol Chem       Date:  1991-03-15       Impact factor: 5.157

10.  Contractile protein phosphorylation predicts human heart disease phenotypes.

Authors:  Lori A Walker; David A Fullerton; Peter M Buttrick
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-05       Impact factor: 4.733

View more
  5 in total

1.  Site-specific acetyl-mimetic modification of cardiac troponin I modulates myofilament relaxation and calcium sensitivity.

Authors:  Ying H Lin; William Schmidt; Kristofer S Fritz; Mark Y Jeong; Anthony Cammarato; D Brian Foster; Brandon J Biesiadecki; Timothy A McKinsey; Kathleen C Woulfe
Journal:  J Mol Cell Cardiol       Date:  2020-01-22       Impact factor: 5.000

2.  Current and Future Directions of Myofilament Regulation.

Authors:  Brandon J Biesiadecki; Jian-Ping Jin
Journal:  Arch Biochem Biophys       Date:  2019-04-30       Impact factor: 4.013

3.  Phosphoproteomic Analysis Reveals Downstream PKA Effectors of AKAP Cypher/ZASP in the Pathogenesis of Dilated Cardiomyopathy.

Authors:  Jialan Lv; Zhicheng Pan; Jian Chen; Rui Xu; Dongfei Wang; Jiaqi Huang; Yang Dong; Jing Jiang; Xiang Yin; Hongqiang Cheng; Xiaogang Guo
Journal:  Front Cardiovasc Med       Date:  2021-12-13

Review 4.  LncRNAs in cardiac hypertrophy: From basic science to clinical application.

Authors:  Lei Liu; Donghui Zhang; Yifei Li
Journal:  J Cell Mol Med       Date:  2020-09-08       Impact factor: 5.310

5.  Improved Cardiac Function and Attenuated Inflammatory Response by Additional Administration of Tirofiban during PCI for ST-Segment Elevation Myocardial Infarction Patients.

Authors:  Jing Zhang; Guomin Ding
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-16       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.